Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta
et al., International Journal of Molecular Sciences, doi:10.3390/ijms222413202 (In Vitro)
In Vitro study of iota-, lambda-, and kappa-carrageenan sulfated polysaccharides extracted from red seaweed on SARS-CoV-2 Wuhan type and variants Alpha, Beta, Gamma and Delta, showing that all three carrageenan types had antiviral activity. Iota-carrageenan had comparable IC50 values against all variants. Authors conclude that iota-carrageenan might be effective for prophylaxis and treatment of SARS-CoV-2 for existing and potentially future variants.
Fröba et al., 12/8/2021, peer-reviewed, 14 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.